Login / Signup

Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial.

Ruth FramptonJennifer R SnaithSamantha L HockingDeborah Jane Holmes-WalkerNicholas OlsenJerry R Greenfield
Published in: Diabetic medicine : a journal of the British Diabetic Association (2024)
The REducing cardiometabolic risk with SEmaglutide in Type 1 diabetes study will investigate whether semaglutide, a long acting glucagon-like peptide receptor agonist, can improve markers of cardiometabolic health in T1D. Underlying mechanisms predicting response, including insulin resistance and incretin hormone status, will also be explored.
Keyphrases